ES2533256T3 - Uso de resiniferatoxina (RTX) para la fabricación de un medicamento para el tratamiento del dolor - Google Patents

Uso de resiniferatoxina (RTX) para la fabricación de un medicamento para el tratamiento del dolor Download PDF

Info

Publication number
ES2533256T3
ES2533256T3 ES04802396.4T ES04802396T ES2533256T3 ES 2533256 T3 ES2533256 T3 ES 2533256T3 ES 04802396 T ES04802396 T ES 04802396T ES 2533256 T3 ES2533256 T3 ES 2533256T3
Authority
ES
Spain
Prior art keywords
pain
case
bone
treatment
tooth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04802396.4T
Other languages
English (en)
Spanish (es)
Inventor
Dominik Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mestex AG
Original Assignee
Mestex AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mestex AG filed Critical Mestex AG
Application granted granted Critical
Publication of ES2533256T3 publication Critical patent/ES2533256T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES04802396.4T 2004-12-28 2004-12-28 Uso de resiniferatoxina (RTX) para la fabricación de un medicamento para el tratamiento del dolor Expired - Lifetime ES2533256T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CH2004/000756 WO2006069451A1 (de) 2004-12-28 2004-12-28 Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels

Publications (1)

Publication Number Publication Date
ES2533256T3 true ES2533256T3 (es) 2015-04-08

Family

ID=34959549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04802396.4T Expired - Lifetime ES2533256T3 (es) 2004-12-28 2004-12-28 Uso de resiniferatoxina (RTX) para la fabricación de un medicamento para el tratamiento del dolor

Country Status (8)

Country Link
US (2) US20080139641A1 (enExample)
EP (1) EP1838301B1 (enExample)
JP (1) JP5775246B2 (enExample)
CA (1) CA2594202C (enExample)
DK (1) DK1838301T3 (enExample)
ES (1) ES2533256T3 (enExample)
PL (1) PL1838301T3 (enExample)
WO (1) WO2006069451A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057930A2 (en) 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with retinoic acid receptor agonists
US8697155B2 (en) * 2008-07-22 2014-04-15 Mayo Foundation For Medical Education And Research Treatment of obesity and related disorders
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
EP3269371A1 (en) 2011-06-10 2018-01-17 Queen Mary University of London Artemisinin and its derivatives for use in the treatment of myocardial infarction or coronary heart disease
US20150190509A1 (en) * 2012-08-03 2015-07-09 Mestex Ag Resiniferatoxin solution
US9603831B2 (en) 2012-12-12 2017-03-28 Queen Mary & Westfield College, University Of London Artemisinin and its derivatives for use in the treatment of kidney disease
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
US11000490B2 (en) 2016-11-02 2021-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
US11400136B2 (en) * 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
WO2019018769A1 (en) 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE
US20190076396A1 (en) * 2017-09-11 2019-03-14 Sorrento Therapeutics, Inc. Formulation of resiniferatoxin
CN113490745A (zh) * 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
WO2020154261A1 (en) * 2019-01-22 2020-07-30 Sorrento Therapeutics, Inc. Method for treating osteoarthritis pain by administering resiniferatoxin
CN110123833A (zh) * 2019-05-31 2019-08-16 龚啸元 一种关节镜手术用灌流液及其制备方法
ES3004508T3 (en) * 2020-04-15 2025-03-12 Gruenenthal Gmbh Resiniferatoxin compositions
US20250228765A1 (en) 2024-01-15 2025-07-17 Gruenenthal Gmbh Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3104085A (en) 1960-07-18 1963-09-17 Ind Paper Log Inc Compressed fibrous articles
US4939149A (en) * 1988-10-24 1990-07-03 The United States Of America As Represented By The Department Of Health And Human Services Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization
US4997853A (en) * 1988-12-02 1991-03-05 Galenpharma, Inc. Method and compositions utilizing capsaicin as an external analgesic
AU5744490A (en) * 1989-05-15 1990-12-18 Afferon Corporation Composition and method for neural desensitization
EP1201241B8 (en) 1997-03-13 2010-10-27 James N. Campbell Compositions containing capsaicin or capsaicin analogues and an anesthetic
GB9711962D0 (en) 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
AU2001297015A1 (en) * 2000-10-15 2002-04-29 Ortho-Mcneil Pharmaceutical, Inc. Improved ligand binding assays for vanilloid receptors
CA2435418A1 (en) * 2001-01-24 2002-08-01 Mestex Ag Use of neurotoxic substances in producing a medicament for treating joint pains
CA2442049C (en) 2001-03-22 2010-06-01 Michael J. Iadarola Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist
US20030104085A1 (en) * 2001-12-05 2003-06-05 Yeomans David C. Methods and compositions for treating back pain
NZ540769A (en) 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
WO2006066419A1 (de) * 2004-12-22 2006-06-29 Mestex Ag Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels

Also Published As

Publication number Publication date
PL1838301T3 (pl) 2015-08-31
EP1838301B1 (de) 2015-01-28
WO2006069451A1 (de) 2006-07-06
US20100196281A1 (en) 2010-08-05
CA2594202C (en) 2013-12-03
DK1838301T3 (en) 2015-04-27
EP1838301A1 (de) 2007-10-03
JP2008525504A (ja) 2008-07-17
US9044452B2 (en) 2015-06-02
CA2594202A1 (en) 2006-07-06
US20080139641A1 (en) 2008-06-12
JP5775246B2 (ja) 2015-09-09

Similar Documents

Publication Publication Date Title
Neer et al. Cuff-tear arthropathy.
Finkelstein et al. Acute posterior fracture dislocations of the shoulder treated with the Neer modification of the McLaughlin procedure
Paley et al. Distraction arthroplasty of the ankle—how far can you stretch the indications?
ES2676318T3 (es) FGF-18 en procedimientos de trasplante de injertos y de ingeniería tisular
Funk Jr et al. Hip problems in fibrous dysplasia.
Kocaoglu et al. Ilizarov fixator for treatment of Legg-Calvé-Perthes disease
Flouzat-Lachaniette et al. Distraction to treat knee osteoarthritis
d'Aubigné Idiopathic Necrosis of the Femoral Head in Adults: Watson-Jones Lecture delivered at the Royal College of Surgeons of England on 26th September 1963
Gdoura et al. Pelvic bone hydatidosis
RU2446766C2 (ru) Способ артродеза голеностопного сустава
Hodik et al. Excision Arthroplasty for Treatment of a Chronic Traumatic Medial Scapulohumeral Joint Luxation in a Dog.
Resnick et al. Resorption of the undersurface of the distal clavicle in rheumatoid arthritis
RU2233132C1 (ru) Способ артродеза голеностопного сустава
Lenehan et al. Lateral approach to the canine elbow by proximal ulnar diaphyseal osteotomy
RU2810418C1 (ru) Способ лечения остеонекроза
RU2797629C1 (ru) Способ моделирования псевдоартроза большеберцовой кости у кроликов
Castro et al. Technique tip: revisiting an alternative method of fixation for first MTP joint arthrodesis
WO2002007620A2 (es) Dispositivo y metodo para la fijacion, compresion y distraccion osea
Jeong et al. Arthroscopic treatment for an osteochondral lesion of the talus
RU2732877C1 (ru) Способ индуцирования очагового остеоартроза в области дистального метаэпифиза бедренной кости у овец
Zhang et al. Single-incision Non-weight-bearing Area Autologous Osteochondral Transplantation for the Treatment of Osteochondral Lesions of the Talus
Li Shoulder Surgery Disasters: How to Manage Complications and Failures After Arthroscopic and Open Shoulder Surgery
ADAMS et al. Surgical repair of metacarpal condylar fractures with palmar osteochondral comminution in two Thoroughbred horses
Kuo et al. The Articular Manifestations of Paget's Disease of Bone A Case Report
RU2234272C2 (ru) Способ артродеза плечевого сустава